- Home
- DXR vs BRNS Comparison
DXR vs BRNS Comparison
Compare DXR & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- BRNS
- Stock Information
- Founded
- DXR 1970
- BRNS 2016
- Country
- DXR United States
- BRNS United Kingdom
- Employees
- DXR N/A
- BRNS N/A
- Industry
- DXR Medical/Dental Instruments
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- BRNS Health Care
- Exchange
- DXR Nasdaq
- BRNS Nasdaq
- Market Cap
- DXR 36.4M
- BRNS 38.7M
- IPO Year
- DXR N/A
- BRNS 2021
- Fundamental
- Price
- DXR $9.25
- BRNS $1.00
- Analyst Decision
- DXR Strong Buy
- BRNS Strong Buy
- Analyst Count
- DXR 1
- BRNS 2
- Target Price
- DXR $25.00
- BRNS $3.00
- AVG Volume (30 Days)
- DXR 2.8K
- BRNS 49.7K
- Earning Date
- DXR 01-01-0001
- BRNS 05-07-2025
- Dividend Yield
- DXR N/A
- BRNS N/A
- EPS Growth
- DXR 86.16
- BRNS N/A
- EPS
- DXR 0.11
- BRNS N/A
- Revenue
- DXR $119,714.00
- BRNS $14,969,000.00
- Revenue This Year
- DXR N/A
- BRNS N/A
- Revenue Next Year
- DXR N/A
- BRNS N/A
- P/E Ratio
- DXR $85.10
- BRNS N/A
- Revenue Growth
- DXR N/A
- BRNS 4381.74
- 52 Week Low
- DXR $6.55
- BRNS $0.64
- 52 Week High
- DXR $10.00
- BRNS $2.14
- Technical
- Relative Strength Index (RSI)
- DXR 73.43
- BRNS 54.11
- Support Level
- DXR $8.29
- BRNS $0.97
- Resistance Level
- DXR $8.13
- BRNS $1.11
- Average True Range (ATR)
- DXR 0.32
- BRNS 0.11
- MACD
- DXR 0.14
- BRNS 0.01
- Stochastic Oscillator
- DXR 100.00
- BRNS 74.78
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.